Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
LGD-3303 is a non-peptide small molecule belonging to the pyrrolo[3,2-f]quinolinone class of selective androgen receptor modulators (SARMs). It has never been approved by the FDA or any regulatory agency for human use, and no human clinical trials have been conducted or registered. LGD-3303 is prohibited under WADA's S1.2 category (Other Anabolic Agents), which covers all SARMs as a class. All available data are preclinical, derived from in vitro AR binding assays and in vivo studies in castrated rats and horses.
0 of 1 vendors lab-verified
Verified purity per dollar — the cheapest that's actually been tested
No prices found for LGD-3303.
Single-vial list prices by default for a fair head-to-head — switch to Multi-vial / bulk for pack pricing. Estimates only; verify at vendor before purchase. For research use only. Not medical advice.
Kimera Chems has the lowest single-vial LGD-3303 price at $0.082/mg among 3 COA-verified vendors on Disclosed Labs. Bulk or multi-vial deals may be lower.
What is the price range for LGD-3303?
Research-grade LGD-3303 is listed at $0.082/mg from 1 verified source on Disclosed Labs.
How are LGD-3303 prices verified on Disclosed Labs?
Every listed vendor holds a Grade C or better trust score, computed independently from lab Certificates of Analysis — not from payments or sponsorships. Prices are scraped and fact-checked daily. Vendors cannot pay to improve their ranking.
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Use the Full safety panel filter to require endotoxin, sterility, and heavy-metals testing on the current batch — not just HPLC purity.
No human data exist for LGD-3303. No completed or registered clinical trials were found on ClinicalTrials.gov, and no PubMed record of a Phase 1 or later human trial exists. In castrated Sprague-Dawley rats, LGD-3303 showed potent anabolic (levator ani muscle) agonist activity but only partial agonist activity on androgenic tissues (ventral prostate, preputial gland); tissue selectivity was maintained across both oral dosing and continuous infusion despite very different plasma exposure-time profiles (Vajda et al. 2009, PMID 19017848). In horses dosed orally at 0.05 mg/kg, eight metabolites (including hydroxylated and carboxylated forms with glucuronic acid conjugates) were tentatively identified in plasma and urine for doping-control purposes, with a monohydroxylated metabolite identified as the most sensitive analytical marker (Nilsson Broberg, Knych, Bondesson et al. 2023, PMID 37224728).
This platform provides informational tools only, not medical advice.
Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator
2009
Equine in vivo metabolite profiling of the selective androgen receptor modulator LGD-3303 for doping control
2023
Prices verified as of July 2026. Actual prices may vary. For research use only.
Disclosed Labs